Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour

Paediatric Respiratory Reviews

Volumn 14, Issue 2, 2013, Pages 130-136

  Resch, Bernhard ^a   Resch, Elisabeth ^a   Müller, Wilhelm ^a  

^a Universitatsklinik fur Kinder und Jugendheilkunde Graz   (Austria)

Author keywords

Lower respiratory tract infection; Preterm infant; Respiratory syncytial virus; Risk factors

Indexed keywords

IMMUNOGLOBULIN; MATERNAL ANTIBODY; PALIVIZUMAB; PLACEBO; VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; ARTIFICIAL VENTILATION; CELLULAR IMMUNITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; EXTRACORPOREAL OXYGENATION; GESTATIONAL AGE; HIGH RISK INFANT; HOSPITAL INFECTION; HOSPITAL READMISSION; HUMAN; IMMUNE SYSTEM; IMMUNOPROPHYLAXIS; INFANT; INFANT MORTALITY; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE UNIT; INTUBATION; LENGTH OF STAY; LUNG DYSPLASIA; LUNG ENDOTHELIUM; LUNG VOLUME; MORBIDITY; PATIENT COMPLIANCE; PREMATURITY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY CARE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SUCTION; VIRAL CLEARANCE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFANT, PREMATURE, DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

HUMANS; INFANT; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RESPIRATORY CARE UNITS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL VACCINES;

EID: 84878563459     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2012.12.005     Document Type: Article

References (85)

1. Dennehy P.H. Epidemiology and Risk Factors. Contemporary Diagnosis and Management of Respiratory Syncytial Virus 2000, 37. Handbooks in Health Care Co, Pennsylvania. L.E. Weisman, J.R. Groothuis (Eds.).
2. Garenne M., Ronsmans C., Dampbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q 1992, 45:180-191.
3. Hall C.B., Walsh E.E., Schnabel K.C., et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990, 162:12831290.
4. Sullender W.M. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 2000, 13:1-15.
5. Dennehy P.H. Epidemiology and Risk Factors. Contemporary Diagnosis and Management of Respiratory Syncytial Virus 2000, 40. Handbooks in Health Care Co, Pennsylvania. L.E. Weisman, J.R. Groothuis (Eds.).
6. McIntosh K. Respiratory syncytial virus infections in infants and children: diagnosis and treatment. Pediatr Rev 1987, 9:191-196.
7. Hall C.B. Respiratory syncytial virus. Textbook of Pediatric Infectious Diseases 1998, 2084-2111. WB Saunders Co, Philadelphia. 4th ed. R.D. Feigin, J.D. Cherry (Eds.).
8. Hall C.B., Douglas R.G., Geiman J.M. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980, 141:98-102.
9. Holberg C.J., Wright A.L., Martinez F.D., et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991, 133:1135-1151.
10. Carlsen K.H., Larsen S., Bjerve O., et al. Acute bronchiolitis: predisposing factors and characterization of infants at risk. Pediatr Pulmonol 1987, 3:153-160.
11. Dennehy P.H. Epidemiology and Risk Factors. Contemporary Diagnosis and Management of Respiratory Syncytial Virus. Pennsylvania 2000, 57. Handbooks in Health Care Co. L.E. Weisman, J.R. Groothuis (Eds.).
12. Shay D.K., Holman R.C., Roosevelt G.E., et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children 1979-1997. J Infect Dis 2000, 183:16-22.
13. Hall C.B., Weinberg G.A., Iwane M.K., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360:588-598.
14. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., Dormitzer M., O'Grady J., Koenig S., Tamura J.K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W.C., Young JF Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176:1215-1224.
15. (AAP 2009) Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124: 1694-1701.
16. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537. The IMpact-RSV Study Group.
17. Wolff D.S., Fiedelman W.M. Respiratory syncytial virus and asthma: is there a link?. J Pediatr Pharm Pract 1999, 4:23-30.
18. Sigurs N., Gustafsson P.M., Bjarnason R., Lundberg F., Schmidt S., Sigurbergsson F., Kjellman B. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005, 171:137-141.
19. Korppi M., Piippo-Savolainen E., Korhonen K., Remes S. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol 2004, 38:155-160.
20. Carpenter T.C., Stenmark K.R. Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis. Pediatr Infect Dis J 2004, 23(suppl 1):S33-S40.
21. Thomas W., Speer C.P. Bronchopulmonary dysplasia. Epidemiology, pathogenesis and treatment. Monatsschr Kinderheilkd 2005, 153:211-219.
22. Groothuis J.R., Gutierrez K.M., Lauer B.A. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988, 82:199-203.
23. Navas L., Wang E., de Carvalho V., Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992, 121:348-354.
24. Wang E.E., Law B.J., Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995, 126:212-219.
25. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997, 93:93-97. The PREVENT Study Group.
26. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduced hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537. The IMpact-RSV Study group.
27. Horn S.D., Smout R.J. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003, 143:133-141.
28. Carbonell-Estrany X., Quero J., Bustos G., et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000, 19:592-597.
29. Thomas M., Bedford-Russell A., Sharland M. Hospitalization for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child 2000, 83:122-127.
30. Greenough A., Cox S., Alexander J., Lenney W., Turnbull F., Burgess S., Chetcuti P.A., Shaw N.J., Woods A., Boorman J., Coles S., Turner J. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001, 85:463-468.
31. Stevens T.P., Sinkin R.A., Hall C.B., Maniscalco W.M., McConnochie K.M. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000, 154:55-61.
32. Liese J.G., Grill E., Fischer B., Roeckl-Wiedmann I., Carr D., Belohradsky B.H. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003, 162:230-236. Munich RSV Study Group.
33. Simon A., Ammann R.A., Wilkesmann A., et al. Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr 2007, 166:1273-1283. DSM RSV Paed Study Group.
34. Flamant C., Hallalel F., Nolent P., Chevalier J.Y., Renolleau S. Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation. Eur J Pediatr 2005, 164:93-98.
35. Pedersen P., Poulsen S. Epidemiology of respiratory syncytial virus infection requiring hospitalisation in East Denmark. Pediatr Infect Dis J 1998, 17:996-1000.
36. Resch B., Gusenleitner W., Mandl C., Müller W. Epidemiology of respiratory syncytial virus infection in Southern Austria. Pediatr Infect Dis J 2000, 19:587-588.
37. Wert S.E. Normal and abnormal structural development of the lung. Fetal and Neonatal Physiology 2004, 784-794. Saunders, Philadelphia. R.A. Polin, W.W. Fox, S.H. Abmann (Eds.).
38. Ballow M., Cates K.L., Rowe J.C., Goetz C., Desbonnet C. Development of the immune system in very low birth weight (less than 1500g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986, 20:899-904.
39. Meert K., Heidemann S., Abella B., Saeniak A. Does prematurity alter the course of respiratory syncytial virus infection?. Crit Care Med 1990, 18:1357-1359.
40. Boyce T.G., Mellen B.G., Mitchel E.F., et al. rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000, 137:865-870.
41. Heikkinen T., Valkonen H., Lehtonen L., et al. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed 2005, 90:F64-F68.
42. Carbonell-Estrany X., Quero J., Bustos G., et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pedaitr infect Dis J 2000, 19:592597.
43. Joffe S., Escobar G.J., Black S.B., et al. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999, 104:894-899.
44. Carbonell-Estrany X., Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001, 20:874-879.
45. Law B.J., Langley J.M., Allen U., et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004, 23:806-814.
46. Figueras-Aloy J., Carbonell-Estrany X., Quero-Jimenez J., et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008, 27:788-793.
47. Joffe S., Escobar G.J., Black S.B., Armstrong M.A., Lieu T.A. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999, 104:894-899.
48. Resch B., Gusenleitner W., Müller W. The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection 2002, 30:193-197.
49. Resch B., Gusenleitner W., Müller W.D., Haas J. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis 2006, 25:120-122.
50. McCormick J., Tubman R. Readmission with respiratory syncytial virus RSV) infection among graduates from a neonatal intensive care unit. Pediatr Pulmonol 2002, 34:262-266.
51. Resch B., Pasnocht A., Gusenleitner W., Müller W. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect 2005, 50:397-403.
52. Nachman S.A., Navaie-Waliser M., Qureshi M.Z. Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: A 3-year follow-up. Pediatrics 1997, 100:E8.
53. Reduction of respiratory syncytial virus hospitalization among premature infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997, 99:93-99. The PREVENT Study group.
54. Pedraz C., Carbonell-Estrany X., Figueras-Aloy J., Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003, 22:823-827. IRIS Study Group.
55. Pedersen O., Herskind A.M., Kamper J., Nielsen J.P., Kristensen K. Rehospitalization for respiratory syncytial virus infection in infants with extremely low gestational age or birthweight in Denmark. Acta Paediatr 2003, 92:240-242.
56. Singleton R., Dooley L., Bruden D., Raelson S., Butler J.C. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J 2003, 22:540-545.
57. Doering G., Gusenleitner W., Belohradsky B.H., Burdach S., Resch B., Liese J.G. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age. Pediatr Infect Dis J 2006, 25:1188-1190.
58. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
59. Stensballe L.G., Devasundaram J.K., Simoes E.A. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J 2003, 22(Suppl):S21-S32.
60. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009, 94:99-103.
61. Colin A.A., McEvoy C., Castile R.G. Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age. Pediatrics 2010, 126:115-128.
62. Duppenthaler A., Gorgievski-Hrisoho M., Aebi C. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalizations for respiratory syncytial virus in infants. Swiss Med Wkly 2001, 131:146-151.
63. Singleton R.J., Petersen K.M., Berner J.E., Schulte E., Chiu K., Lilly C.M., et al. Hospitalizations for respiratory syncytial virus infection in Alaska Native children. Pediatr Infect Dis J 1995, 14:26-30.
64. Banerji A., Lanctôt K.L., Paes B.A., Masoud S.T., Tam D.Y., Macdonald W.A., Roberts A. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr Infect Dis J 2009, 28:702-706.
65. Willson D.F., Landrigan C.P., Horn S.D., Smout R.J. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003, 143(Suppl):S142-S149.
66. Douglas M.Fleming, Rachel S.Pannell, Kenneth W.Cross Mortality in children from influenza and respiratory syncytial virus. J Epidemiol Community Health 2005, 59:586-590.
67. Howard T.S., Hoffman L.H., Stang P.E., Simoes E.A. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr 2000, 137:227-232.
68. Sampalis J.S. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003, 143(Suppl):S150-S156.
69. American Academy of Pediatrics Respiratory syncytial virus. Red Book: 2009 Report of the Committee on Infectious Diseases 2009, American Academy of Pediatrics, Elk Grove, IL. 28th ed. L. Pickering, C. Baker, D.W. Kimberlin (Eds.).
70. Golombek S.G., Berning F., Lagamma E.F. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J 2004, 23:318-322.
71. Paolo Manzoni, Ugo Sala, Giovanna Gomirato, Alessandra Coscia and Claudio Fabris Optimal Timing and Dosing Intervals of Palivizumab in Premature Neonates: Still Some Work to Do. Pediatrics 2005; 115;1439-1440.
72. Wu S.Y., Bonaparte J., Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics 2004, 114:e554.
73. Parnes C., Guillermin J., Habersang R., et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003, 35:484-489. Palivizumab Outcomes Registry Study Group.
74. Prescott W.A., Doloresco F., Brown J., et al. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010, 28:279-293.
75. Elhassan N.O., Sorbero M.E., Hall C.B., et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006, 160:1070-1076.
76. Joffe S., Ray G.T., Escobar G.J., et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999, 104:419-427.
77. Yount L.E., Mahle W.T. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004, 114:1606-1611.
78. Wang D., Cummins C., Bayliss S., et al. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008, 12:1-108.
79. Nuijten M.J., Wittenberg W., Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007, 25:55-71.
80. Simoes E.A., Carbonell-Estrany X., Rieger C.H., et al. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol 2010, 126:256-262.
81. Simoes E.A., Groothuis J.R., Carbonell-Estrany X., et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007, 151:34-42. 42.e1.
82. Meissner H.C., Long S.S. Respiratory syncytial virus infection and recurrent wheezing: a complex relationship. J Pediatr 2007, 151:6-7.
83. Panozzo C.A., Stockman L.J., Curns A.T., et al. Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis. Pediatrics 2010, 126:e116-e123.
84. Resch B., Gusenleitner W., Nuijten M.J.C., Lebmeier M., Wittenberg W. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008, 30:749-760.
85. Resch B., Sommer C., Nuijten M.J.C., Seidinger S., Walter E., Schoellbauer V., Mueller W.D. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children based on long-term epidemiological data from Austria. Pediatr Infect Dis J 2012, 31(1):e1-e8. 10.1097/INF.0b013e318235455b.